HLA-Releasing Metalloproteinase in Allograft Rejection

同种异体移植排斥中 HLA 释放金属蛋白酶

基本信息

  • 批准号:
    7373536
  • 负责人:
  • 金额:
    $ 32.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We have previously described the metalloproteinase-mediated pathway of soluble MHC class I release and proposed its role in transplantation. We found that the release of soluble MHC class I is mediated by a disintegrin and metalloprotease family member, ADAM17. Endothelial cells (EC) co-cultured with allogeneic T cells up-regulate specific activation markers and both the expression and activity of ADAM 17. This activation is driven by interferon-gamma and culminates in the release of soluble MHC class I proteins by EC. However, at least one other metalloproteinase distinct from ADAM17 is fully capable of releasing soluble MHC class I. Its activity may be regulated by cytokines in a tissue-specific manner. Screening of a human leukemia expression library with our mAb that blocks the release of soluble MHC class I led to identification of a novel protein BC036469 with yet unknown function. This ubiquitously expressed protein may participate in the mechanism of soluble MHC class I release by mediating specific enzyme/substrate interactions and its function may be regulated by cell-specific cytokines in different tissues. Three independent aims are designed to address these questions. First, we will identify cytokine-inducible metalloproteinases capable of processing MHC class I by using a panel of ADAM-deficient cell lines and by DNA microarray analysis. Second, the function of BC036469 protein will be determined by overexpressing wild type and deletion mutants, and by disrupting expression of the endogenous protein with specific siRNA. Finally, we will determine the sites required for productive enzyme/substrate interactions within alpha 3 and transmembrane domains of MHC class I and test the ability of specific peptides to inhibit the interaction. The predicted role of soluble MHC class I in antigen presentation will be tested using the trans-vivo delayed-type hypersensitivity assay in the linked suppression model of immune regulation by HLA-A2- restricted CD8 low avidity T regulator cells controlling transplantation tolerance.
描述(由申请人提供):我们之前已经描述了金属蛋白酶介导的可溶性MHC I类释放途径,并提出了其在移植中的作用。我们发现可溶性MHC I类的释放是由崩解素和金属蛋白酶家族成员ADAM17介导的。内皮细胞(EC)与异体T细胞共培养可上调特异性激活标记物以及adam17的表达和活性。这种激活是由干扰素驱动的,并在EC释放可溶性MHC I类蛋白时达到高潮。然而,至少有一种与ADAM17不同的其他金属蛋白酶完全能够释放可溶性MHC i类,其活性可能受细胞因子以组织特异性方式调节。用我们的mAb筛选人类白血病表达文库,阻断可溶性MHC类I的释放,鉴定出一种功能未知的新蛋白BC036469。这种无处不在表达的蛋白可能通过介导特异性酶/底物相互作用参与可溶性MHC I类释放机制,其功能可能受到不同组织中细胞特异性细胞因子的调节。三个独立的目标旨在解决这些问题。首先,我们将通过使用一组adam缺陷细胞系和DNA微阵列分析来鉴定能够处理MHC I类的细胞因子诱导的金属蛋白酶。其次,BC036469蛋白的功能将通过过表达野生型和缺失型突变体,以及用特异性siRNA破坏内源蛋白的表达来确定。最后,我们将确定α 3和MHC I类跨膜结构域内生产酶/底物相互作用所需的位点,并测试特定肽抑制相互作用的能力。可溶性MHC I类在抗原呈递中的预测作用将在HLA-A2限制性CD8低亲和力T调节细胞控制移植耐受的免疫调节相关抑制模型中使用跨体延迟型超敏反应试验进行测试。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YURI BUSHKIN其他文献

YURI BUSHKIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YURI BUSHKIN', 18)}}的其他基金

Rapid Analysis of Single T Cell Immunity Signatures in Tuberculosis
结核病中单 T 细胞免疫特征的快速分析
  • 批准号:
    8706329
  • 财政年份:
    2013
  • 资助金额:
    $ 32.95万
  • 项目类别:
Rapid Analysis of Single T Cell Immunity Signatures in Tuberculosis
结核病中单 T 细胞免疫特征的快速分析
  • 批准号:
    8721333
  • 财政年份:
    2012
  • 资助金额:
    $ 32.95万
  • 项目类别:
Rapid Analysis of Single T Cell Immunity Signatures in Tuberculosis
结核病中单 T 细胞免疫特征的快速分析
  • 批准号:
    8541693
  • 财政年份:
    2012
  • 资助金额:
    $ 32.95万
  • 项目类别:
Rapid Analysis of Single T Cell Immunity Signatures in Tuberculosis
结核病中单 T 细胞免疫特征的快速分析
  • 批准号:
    8414032
  • 财政年份:
    2012
  • 资助金额:
    $ 32.95万
  • 项目类别:
HLA-Releasing Metalloproteinase in Allograft Rejection
同种异体移植排斥中 HLA 释放金属蛋白酶
  • 批准号:
    7923507
  • 财政年份:
    2009
  • 资助金额:
    $ 32.95万
  • 项目类别:
Novel targets for vaccines against tuberculosis
结核病疫苗的新靶标
  • 批准号:
    6859051
  • 财政年份:
    2005
  • 资助金额:
    $ 32.95万
  • 项目类别:
Novel targets for vaccines against tuberculosis
结核病疫苗的新靶点
  • 批准号:
    7386290
  • 财政年份:
    2005
  • 资助金额:
    $ 32.95万
  • 项目类别:
HLA-Releasing Metalloproteinase in Allograft Rejection
同种异体移植排斥中 HLA 释放金属蛋白酶
  • 批准号:
    6871672
  • 财政年份:
    2005
  • 资助金额:
    $ 32.95万
  • 项目类别:
HLA-Releasing Metalloproteinase in Allograft Rejection
同种异体移植排斥中 HLA 释放金属蛋白酶
  • 批准号:
    7454961
  • 财政年份:
    2005
  • 资助金额:
    $ 32.95万
  • 项目类别:
HLA-Releasing Metalloproteinase in Allograft Rejection
同种异体移植排斥中 HLA 释放金属蛋白酶
  • 批准号:
    7769785
  • 财政年份:
    2005
  • 资助金额:
    $ 32.95万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.95万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了